HCW Biologics Inc. Net Change in Cash
HCW Biologics Inc. (HCWB) reported Net Change in Cash of -$1.21 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-14
- HCW Biologics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$723.59K.
- HCW Biologics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$3.57M, a 829.48% decline year-over-year.
- HCW Biologics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $488.98K.
- HCW Biologics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$3.94M, a 161.64% decline year-over-year.
- HCW Biologics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$2.72M, a 352.17% decline from fiscal 2024.
- HCW Biologics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $1.08M.
- HCW Biologics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$18.73M, a 276.78% decline from fiscal 2022.
- HCW Biologics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $10.60M, a 223.55% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.21M 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | -$723.59K 10-Q/A · filed 2026-08-14 | |||
| 2025-12-31 | -$2.72M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | -$3.58M 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | -$2.24M 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | -$3.57M 10-Q/A · filed 2026-08-14 | |||
| 2024-12-31 | $1.08M 10-K · filed 2026-03-31 | |||
| 2024-09-30 | -$2.60M 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | -$2.43M 10-Q · filed 2025-08-18 | |||
| 2024-03-31 | $488.98K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$18.73M 10-K · filed 2025-03-28 | |||
| 2023-09-30 | -$11.11M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$14.88M 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | -$3.94M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $10.60M 10-K/A · filed 2024-05-15 | |||
| 2022-09-30 | $14.49M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | $3.69M 10-Q · filed 2023-08-11 | |||
| 2022-03-31 | $6.39M 10-Q/A · filed 2023-08-10 | |||
| 2021-12-31 | $3.27M 10-K · filed 2023-03-28 | |||
| 2021-09-30 | $6.67M 10-Q · filed 2022-11-07 | |||
| 2021-06-30 | -$3.40M 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |